BlackRock Amends RYTM Stake, Maintains Passive Position
Ticker: RYTM · Form: SC 13G/A · Filed: Jan 24, 2024 · CIK: 1649904
| Field | Detail |
|---|---|
| Company | Rhythm Pharmaceuticals, Inc. (RYTM) |
| Form Type | SC 13G/A |
| Filed Date | Jan 24, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investing
TL;DR
**BlackRock still owns a big chunk of RYTM, signaling long-term institutional belief.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 24, 2024, indicating its ownership of RHYTHM PHARMACEUTICALS, INC. (NASDAQ: RYTM) Common Stock as of December 31, 2023. This amendment (Amendment No. 2) updates their previous filing, confirming their continued significant, but passive, stake in the pharmaceutical company. This matters to investors because BlackRock is one of the world's largest asset managers, and their sustained position suggests a long-term, institutional confidence in RYTM's prospects, even if their percentage ownership has slightly changed.
Why It Matters
This filing confirms BlackRock's ongoing substantial investment in RHYTHM PHARMACEUTICALS, signaling institutional confidence that could influence other investors.
Risk Assessment
Risk Level: low — This is a routine update from a passive institutional investor and does not indicate any immediate change in company fundamentals or significant new risks.
Analyst Insight
Investors should view this as a routine update from a major institutional holder, reinforcing existing sentiment rather than signaling a new catalyst. It suggests BlackRock's continued belief in RYTM's long-term value, but doesn't imply any immediate price movement.
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- RHYTHM PHARMACEUTICALS, INC. (company) — the subject company whose stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 24, 2024 (date) — the filing date of the SC 13G/A
- Amendment No: 2 (number) — the specific amendment number for this filing
Forward-Looking Statements
- BlackRock will likely maintain a significant, passive stake in RHYTHM PHARMACEUTICALS, INC. for the foreseeable future. (BlackRock Inc.) — high confidence, target: December 31, 2024
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G, filed under the Securities Exchange Act of 1934.
Who is the 'Reporting Person' in this filing?
The 'Reporting Person' is BlackRock Inc., identified by the Central Index Key (CIK) 0001364742.
What is the 'Subject Company' whose securities are being reported?
The 'Subject Company' is RHYTHM PHARMACEUTICALS, INC., identified by the Central Index Key (CIK) 0001649904.
What is the 'Title of Class of Securities' being reported?
The 'Title of Class of Securities' is Common Stock of RHYTHM PHARMACEUTICALS, INC.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 24, 2024 regarding RHYTHM PHARMACEUTICALS, INC. (RYTM).